BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34067671)

  • 21. Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD.
    Bui HM; Enis D; Robciuc MR; Nurmi HJ; Cohen J; Chen M; Yang Y; Dhillon V; Johnson K; Zhang H; Kirkpatrick R; Traxler E; Anisimov A; Alitalo K; Kahn ML
    J Clin Invest; 2016 Jun; 126(6):2167-80. PubMed ID: 27159393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular controls of lymphatic VEGFR3 signaling.
    Deng Y; Zhang X; Simons M
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):421-9. PubMed ID: 25524775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor necrosis factor superfamily 15 promotes lymphatic metastasis via upregulation of vascular endothelial growth factor-C in a mouse model of lung cancer.
    Qin T; Huang D; Liu Z; Zhang X; Jia Y; Xian CJ; Li K
    Cancer Sci; 2018 Aug; 109(8):2469-2478. PubMed ID: 29890027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
    Duignan IJ; Corcoran E; Pennello A; Plym MJ; Amatulli M; Claros N; Iacolina M; Youssoufian H; Witte L; Samakoglu S; Schwartz J; Surguladze D; Tonra JR
    Neoplasia; 2011 Jan; 13(1):49-59. PubMed ID: 21245940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor-C secreted by pancreatic cancer cell line promotes lymphatic endothelial cell migration in an in vitro model of tumor lymphangiogenesis.
    Ochi N; Matsuo Y; Sawai H; Yasuda A; Takahashi H; Sato M; Funahashi H; Okada Y; Manabe T
    Pancreas; 2007 May; 34(4):444-51. PubMed ID: 17446844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
    Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
    Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of vascular endothelial growth factor receptor 3 (VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia-induced lymph node metastases in cervix cancer.
    Chaudary N; Milosevic M; Hill RP
    Gynecol Oncol; 2011 Nov; 123(2):393-400. PubMed ID: 21839498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
    Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
    Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropilin-2 mediates lymphangiogenesis of colorectal carcinoma via a VEGFC/VEGFR3 independent signaling.
    Ou JJ; Wei X; Peng Y; Zha L; Zhou RB; Shi H; Zhou Q; Liang HJ
    Cancer Lett; 2015 Mar; 358(2):200-209. PubMed ID: 25543087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
    Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
    Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.
    Yamasaki T; Kamba T; Kanno T; Inoue T; Shibasaki N; Arakaki R; Yamada T; Kondo K; Kamoto T; Nishiyama H; Ogawa O; Nakamura E
    Cancer Sci; 2012 Nov; 103(11):2027-37. PubMed ID: 22931246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
    Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
    Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-128-3p directly targets VEGFC/VEGFR3 to modulate the proliferation of lymphatic endothelial cells through Ca
    Zhou J; He Z; Guo L; Zeng J; Liang P; Ren L; Zhang M; Zhang P; Huang X
    Int J Biochem Cell Biol; 2018 Sep; 102():51-58. PubMed ID: 29777777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
    Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
    Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ADAMTS1 inhibits lymphangiogenesis by attenuating phosphorylation of the lymphatic endothelial cell-specific VEGF receptor.
    Inagaki J; Takahashi K; Ogawa H; Asano K; Faruk Hatipoglu O; Cilek MZ; Obika M; Ohtsuki T; Hofmann M; Kusachi S; Ninomiya Y; Hirohata S
    Exp Cell Res; 2014 May; 323(2):263-75. PubMed ID: 24631293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway.
    Choi JU; Chung SW; Al-Hilal TA; Alam F; Park J; Mahmud F; Jeong JH; Kim SY; Byun Y
    Biomaterials; 2017 Sep; 139():56-66. PubMed ID: 28586719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer.
    Tacconi C; Ungaro F; Correale C; Arena V; Massimino L; Detmar M; Spinelli A; Carvello M; Mazzone M; Oliveira AI; Rubbino F; Garlatti V; Spanò S; Lugli E; Colombo FS; Malesci A; Peyrin-Biroulet L; Vetrano S; Danese S; D'Alessio S
    Cancer Res; 2019 Aug; 79(16):4196-4210. PubMed ID: 31239267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathway-related molecules of VEGFC/D-VEGFR3/NRP2 axis in tumor lymphangiogenesis and lymphatic metastasis.
    Wang J; Huang Y; Zhang J; Wei Y; Mahoud S; Bakheet AM; Wang L; Zhou S; Tang J
    Clin Chim Acta; 2016 Oct; 461():165-71. PubMed ID: 27527412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.